Research Group : Bergamaschi R., Giorgio Sandrini

The advent of a new generation of drugs has changed the Multiple Sclerosis (MS) treatment scenario. There is a current and growing emphasis on obtaining data beyond phase III clinical trial.
Analysis of the safety, efficacy and tolerability of new and emerging immune-targeted drugs for the treatment of MS in real word settings
Analysis and comparison of the effectiveness of first and new generation drugs for MS in different MS population applying a Bayesian statistical approach.
Explore the effect of new generation drugs on post-transcriptional mechanisms via ex vivo and in vitro experiments.

Recent Publications:

• Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. Bergamaschi R, Quaglini S, Trojano M, Amato MP, Tavazzi E, Paolicelli D, Zipoli V, Romani A, Fuiani A, Portaccio E, Berzuini C, Montomoli C, Bastianello S, Cosi V. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):757-9.
• BREMSO: a simple score to predict early the natural course of multiple sclerosis. Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand’Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, Lechner-Scott J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, Trojano M. Eur J Neurol. 2015 Jun;22(6):981-9.
• What’s new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A. Pharmacol Res. 2017 Jun;120:279-293.